{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T16:47:27Z","timestamp":1774889247843,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15760-6","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T07:05:03Z","timestamp":1771830303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The prognostic value of metabolic heterogeneity parameter coefficient of variation (COV) of baseline 18F-FDG PET\/CT in newly diagnosed diffuse large B-cell lymphoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Siqi","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhua","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"15760_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G, Diffuse Large B-C, Lymphoma. N Engl J Med. 2021;384:842\u201358. https:\/\/doi.org\/10.1056\/NEJMra2027612.","journal-title":"N Engl J Med"},{"key":"15760_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","volume":"50","author":"S Li","year":"2018","unstructured":"Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50:74\u201387. https:\/\/doi.org\/10.1016\/j.pathol.2017.09.006.","journal-title":"Pathology"},{"key":"15760_CR3","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","volume":"23","author":"LH Sehn","year":"2005","unstructured":"Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027\u201333.","journal-title":"J Clin Oncol"},{"key":"15760_CR4","doi-asserted-by":"publisher","first-page":"204062072198957","DOI":"10.1177\/2040620721989579","volume":"12","author":"M Candelaria","year":"2021","unstructured":"Candelaria M, Due\u00f1as-Gonzalez A. Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. Ther Adv Hematol. 2021;12:2040620721989579. https:\/\/doi.org\/10.1177\/2040620721989579.","journal-title":"Ther Adv Hematol"},{"key":"15760_CR5","doi-asserted-by":"publisher","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the groupe d\u2019etudes des lymphomes de l\u2019adulte. Blood. 2010;116:2040\u20135. https:\/\/doi.org\/10.1182\/blood-2010-03-276246.","DOI":"10.1182\/blood-2010-03-276246"},{"key":"15760_CR6","doi-asserted-by":"publisher","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184\u201390. https:\/\/doi.org\/10.1200\/JCO.2010.28.1618.","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"15760_CR7","doi-asserted-by":"publisher","unstructured":"Pfreundschuh M, Kuhnt E, Tr\u00fcmper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera international trial (MInT) group. Lancet Oncol. 2011;12:1013\u201322. https:\/\/doi.org\/10.1016\/S1470-2045(11)70235-2.","DOI":"10.1016\/S1470-2045(11)70235-2"},{"key":"15760_CR8","doi-asserted-by":"publisher","unstructured":"Pribluda A, de la Cruz CC, Jackson EL. Intratumoral heterogeneity: from diversity comes resistance. Clin Cancer Res. 2015;21:2916\u201323. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1213.","DOI":"10.1158\/1078-0432.CCR-14-1213"},{"key":"15760_CR9","doi-asserted-by":"publisher","unstructured":"Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.015.","DOI":"10.1016\/j.ccell.2020.03.015"},{"key":"15760_CR10","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679\u201390. https:\/\/doi.org\/10.1038\/s41591-018-0016-8.","journal-title":"Nat Med"},{"key":"15760_CR11","doi-asserted-by":"publisher","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-Cell lymphoma. N Engl J Med. 2018;378:1396\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa1801445.","DOI":"10.1056\/NEJMoa1801445"},{"key":"15760_CR12","doi-asserted-by":"publisher","unstructured":"Hai P, Imai T, Xu S, Zhang R, Aft RL, Zou J, et al. High-throughput, label-free, single-cell photoacoustic microscopy of intratumoral metabolic heterogeneity. Nat Biomed Eng. 2019;3:381\u201391. https:\/\/doi.org\/10.1038\/s41551-019-0376-5.","DOI":"10.1038\/s41551-019-0376-5"},{"key":"15760_CR13","doi-asserted-by":"publisher","unstructured":"Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116\u201325. https:\/\/doi.org\/10.1093\/annonc\/mdv304.","DOI":"10.1093\/annonc\/mdv304"},{"key":"15760_CR14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ijrobp.2005.02.009","volume":"62","author":"A Pugachev","year":"2005","unstructured":"Pugachev A, Ruan S, Carlin S, Larson SM, Campa J, Ling CC, et al. Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys. 2005;62:545\u201353.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15760_CR15","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00259-011-1787-z","volume":"38","author":"S Basu","year":"2011","unstructured":"Basu S, Kwee TC, Gatenby R, Saboury B, Torigian DA, Alavi A. Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders. Eur J Nucl Med Mol Imaging. 2011;38:987\u201391. https:\/\/doi.org\/10.1007\/s00259-011-1787-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"15760_CR16","doi-asserted-by":"publisher","unstructured":"Walsh AJ, Sharick JT, Skala MC. Imaging intratumoral metabolic heterogeneity. Nat Biomed Eng. 2019;3:333\u20134. https:\/\/doi.org\/10.1038\/s41551-019-0398-z.","DOI":"10.1038\/s41551-019-0398-z"},{"key":"15760_CR17","doi-asserted-by":"publisher","unstructured":"O\u2019Connor JPB. Cancer heterogeneity and imaging. Semin Cell Dev Biol. 2017;64:48\u201357. https:\/\/doi.org\/10.1016\/j.semcdb.2016.10.001.","DOI":"10.1016\/j.semcdb.2016.10.001"},{"key":"15760_CR18","doi-asserted-by":"publisher","unstructured":"Terao T, Machida Y, Hirata K, Kuzume A, Tabata R, Tsushima T, et al. Prognostic impact of metabolic heterogeneity in patients with newly diagnosed multiple myeloma using 18F-FDG PET\/CT. Clin Nucl Med. 2021;46:790\u20136. https:\/\/doi.org\/10.1097\/RLU.0000000000003773.","DOI":"10.1097\/RLU.0000000000003773"},{"key":"15760_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40644-023-00608-0","volume":"23","author":"G Ma","year":"2023","unstructured":"Ma G, You S, Xie Y, Gu B, Liu C, Hu X, et al. Pretreatment 18F-FDG uptake heterogeneity May predict treatment outcome of combined trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer. Cancer Imaging. 2023;23:90. https:\/\/doi.org\/10.1186\/s40644-023-00608-0.","journal-title":"Cancer Imaging"},{"key":"15760_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13142448","author":"S Pellegrino","year":"2023","unstructured":"Pellegrino S, Fonti R, Hakkak Moghadam Torbati A, Bologna R, Morra R, Damiano V, et al. Heterogeneity of glycolytic phenotype determined by 18F-FDG PET\/CT using coefficient of variation in patients with advanced Non-Small cell lung cancer. Diagnostics (Basel). 2023. https:\/\/doi.org\/10.3390\/diagnostics13142448.","journal-title":"Diagnostics (Basel)"},{"key":"15760_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020279","author":"S Pellegrino","year":"2024","unstructured":"Pellegrino S, Fonti R, Vallone C, Morra R, Matano E, De Placido S, et al. Coefficient of variation in metastatic lymph nodes determined by 18F-FDG PET\/CT in patients with advanced NSCLC: combination with coefficient of variation in primary tumors. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16020279.","journal-title":"Cancers (Basel)"},{"key":"15760_CR22","doi-asserted-by":"publisher","unstructured":"Pellegrino S, Origlia D, Di Donna E, Lamagna M, Della Pepa R, Pane F, et al. Coefficient of variation and texture analysis of 18F-FDG PET\/CT images for the prediction of outcome in patients with multiple myeloma. Ann Hematol. 2024. https:\/\/doi.org\/10.1007\/s00277-024-05905-7.","DOI":"10.1007\/s00277-024-05905-7"},{"key":"15760_CR23","doi-asserted-by":"publisher","unstructured":"Sperry BW, Tamarappoo BK, Oldan JD, Javed O, Culver DA, Brunken R, et al. Prognostic impact of Extent, Severity, and heterogeneity of abnormalities on 18F-FDG PET scans for suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2018;11:336\u201345. https:\/\/doi.org\/10.1016\/j.jcmg.2017.04.020.","DOI":"10.1016\/j.jcmg.2017.04.020"},{"key":"15760_CR24","doi-asserted-by":"crossref","unstructured":"Moon SH, Cho YS, Son Y-I, Ahn YC, Ahn M-J, Choi JY, et al. Value of 18F-FDG heterogeneity for discerning metastatic from benign lymph nodes in nasopharyngeal carcinoma patients with suspected recurrence. Br J Radiol. 2016;89:20160109.","DOI":"10.1259\/bjr.20160109"},{"key":"15760_CR25","doi-asserted-by":"publisher","unstructured":"Meignan M, Sasanelli M, Casasnovas RO, Luminari S, Fioroni F, Coriani C, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on Phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014;41:1113\u201322. https:\/\/doi.org\/10.1007\/s00259-014-2705-y.","DOI":"10.1007\/s00259-014-2705-y"},{"key":"15760_CR26","doi-asserted-by":"publisher","unstructured":"Pahk K, Chung JH, Yi E, Kim S, Lee SH. Metabolic tumor heterogeneity analysis by F-18 FDG PET\/CT predicts mediastinal lymph node metastasis in non-small cell lung cancer patients with clinically suspected N2. Eur J Radiol. 2018;106:145\u20139. https:\/\/doi.org\/10.1016\/j.ejrad.2018.07.028.","DOI":"10.1016\/j.ejrad.2018.07.028"},{"key":"15760_CR27","doi-asserted-by":"publisher","unstructured":"Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol. 2011;29:1844\u201354. https:\/\/doi.org\/10.1200\/JCO.2010.32.5225.","DOI":"10.1200\/JCO.2010.32.5225"},{"key":"15760_CR28","doi-asserted-by":"crossref","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, M\u00fceller SP et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048-58.","DOI":"10.1200\/JCO.2013.53.5229"},{"key":"15760_CR29","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cncr.27855","volume":"119","author":"TM Kim","year":"2013","unstructured":"Kim TM, Paeng JC, Chun IK, Keam B, Jeon YK, Lee S-H, et al. Total lesion Glycolysis in positron emission tomography is a better predictor of outcome than the international prognostic index for patients with diffuse large B cell lymphoma. Cancer. 2013;119:1195\u2013202. https:\/\/doi.org\/10.1002\/cncr.27855.","journal-title":"Cancer"},{"key":"15760_CR30","doi-asserted-by":"publisher","first-page":"728","DOI":"10.2967\/jnumed.115.166769","volume":"57","author":"H Sch\u00f6der","year":"2016","unstructured":"Sch\u00f6der H, Zelenetz AD, Hamlin P, Gavane S, Horwitz S, Matasar M, et al. Prospective study of 3\u2019-Deoxy-3\u2019-18F-Fluorothymidine PET for early interim response assessment in Advanced-Stage B-Cell lymphoma. J Nucl Med. 2016;57:728\u201334. https:\/\/doi.org\/10.2967\/jnumed.115.166769.","journal-title":"J Nucl Med"},{"key":"15760_CR31","doi-asserted-by":"publisher","unstructured":"Xiao Z, Dai Z, Locasale JW. Metabolic landscape of the tumor microenvironment at single cell resolution. Nat Commun. 2019;10:3763. https:\/\/doi.org\/10.1038\/s41467-019-11738-0.","DOI":"10.1038\/s41467-019-11738-0"},{"key":"15760_CR32","doi-asserted-by":"publisher","unstructured":"Miyazaki Y, Nawa Y, Miyagawa M, Kohashi S, Nakase K, Yasukawa M, et al. Maximum standard uptake value of 18F-fluorodeoxyglucose positron emission tomography is a prognostic factor for progression-free survival of newly diagnosed patients with diffuse large B cell lymphoma. Ann Hematol. 2013;92:239\u201344. https:\/\/doi.org\/10.1007\/s00277-012-1602-3.","DOI":"10.1007\/s00277-012-1602-3"},{"key":"15760_CR33","doi-asserted-by":"publisher","unstructured":"Adams HJA, de Klerk JMH, Fijnheer R, Heggelman BGF, Dubois SV, Nievelstein RAJ, et al. Prognostic superiority of the National comprehensive cancer network international prognostic index over pretreatment whole-body volumetric-metabolic FDG-PET\/CT metrics in diffuse large B-cell lymphoma. Eur J Haematol. 2015;94:532\u20139. https:\/\/doi.org\/10.1111\/ejh.12467.","DOI":"10.1111\/ejh.12467"},{"key":"15760_CR34","doi-asserted-by":"publisher","unstructured":"Bundschuh RA, Dinges J, Neumann L, Seyfried M, Zs\u00f3t\u00e9r N, Papp L, et al. Textural parameters of tumor heterogeneity in \u00b9\u2078F-FDG PET\/CT for therapy response assessment and prognosis in patients with locally advanced rectal cancer. J Nucl Med. 2014;55:891\u20137. https:\/\/doi.org\/10.2967\/jnumed.113.127340.","DOI":"10.2967\/jnumed.113.127340"},{"key":"15760_CR35","doi-asserted-by":"publisher","unstructured":"Mikhaeel NG, Smith D, Dunn JT, Phillips M, M\u00f8ller H, Fields PA, et al. Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43:1209\u201319. https:\/\/doi.org\/10.1007\/s00259-016-3315-7.","DOI":"10.1007\/s00259-016-3315-7"},{"key":"15760_CR36","doi-asserted-by":"publisher","unstructured":"Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2011;29:1452\u20137. https:\/\/doi.org\/10.1200\/JCO.2010.33.3419.","DOI":"10.1200\/JCO.2010.33.3419"},{"key":"15760_CR37","doi-asserted-by":"crossref","unstructured":"Haioun C, Itti E, Rahmouni A, Brice P, Rain J-D, Belhadj K, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376\u201381.","DOI":"10.1182\/blood-2005-01-0272"},{"key":"15760_CR38","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"A predictive model","year":"1993","unstructured":"A predictive model. For aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329:987\u201394.","journal-title":"N Engl J Med"},{"key":"15760_CR39","doi-asserted-by":"publisher","unstructured":"Adams HJA, Kwee TC, Fijnheer R, Dubois SV, Nievelstein RAJ, de Klerk JMH. Diffusely increased bone marrow FDG uptake in recently untreated lymphoma: incidence and relevance. Eur J Haematol. 2015;95:83\u20139. https:\/\/doi.org\/10.1111\/ejh.12483.","DOI":"10.1111\/ejh.12483"},{"key":"15760_CR40","doi-asserted-by":"crossref","unstructured":"Menon NC, Buchanan JG. Bilateral Trephine bone marrow biopsies in hodgkin\u2019s and non-Hodgkin\u2019s lymphoma. Pathology. 1979;11:53\u20137.","DOI":"10.3109\/00313027909063538"},{"key":"15760_CR41","doi-asserted-by":"publisher","first-page":"365","DOI":"10.7326\/0003-4819-82-3-365","volume":"82","author":"RD Brunning","year":"1975","unstructured":"Brunning RD, Bloomfield CD, McKenna RW, Peterson LA. Bilateral Trephine bone marrow biopsies in lymphoma and other neoplastic diseases. Ann Intern Med. 1975;82:365\u20136.","journal-title":"Ann Intern Med"},{"key":"15760_CR42","doi-asserted-by":"publisher","unstructured":"Chen Y-K, Yeh C-L, Tsui C-C, Liang J-A, Chen J-H, Kao C-H. F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis. Clin Nucl Med. 2011;36:553\u20139. https:\/\/doi.org\/10.1097\/RLU.0b013e318217aeff.","DOI":"10.1097\/RLU.0b013e318217aeff"},{"key":"15760_CR43","doi-asserted-by":"publisher","unstructured":"Khan AB, Barrington SF, Mikhaeel NG, Hunt AA, Cameron L, Morris T, et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood. 2013;122:61\u20137. https:\/\/doi.org\/10.1182\/blood-2012-12-473389.","DOI":"10.1182\/blood-2012-12-473389"},{"key":"15760_CR44","doi-asserted-by":"publisher","unstructured":"Berthet L, Cochet A, Kanoun S, Berriolo-Riedinger A, Humbert O, Toubeau M, et al. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET\/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med. 2013;54:1244\u201350. https:\/\/doi.org\/10.2967\/jnumed.112.114710.","DOI":"10.2967\/jnumed.112.114710"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15760-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15760-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15760-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:46:04Z","timestamp":1774885564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15760-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15760"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15760-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received approval from the Institutional Ethical Review Board of The Third Affiliated Hospital of Sun Yat-Sen University, which also waived the requirement for informed consent. The study\u2019s methodology was based on the International Conference on Harmonization\u2019s Good Clinical Practice standards and the 1964 Helsinki Declaration, including its later revisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"421"}}